Literature DB >> 17164792

Adenovirus-based prime-boost immunization for rapid vaccination against anthrax.

Michael J McConnell1, Philip C Hanna, Michael J Imperiale.   

Abstract

Prime-boost vaccination using plasmid DNA and replication-defective adenovirus vectors has emerged as a highly effective strategy for vaccinating against viral pathogens. However, its ability to provide protection against bacterial disease has never been assessed. Here we evaluate prime-boost vaccination approaches for immunizing against anthrax. We show that mice primed with DNA and boosted with an adenovirus vector, both expressing domain four of Bacillus anthracis protective antigen (PA), have higher antibody and toxin-neutralizing titers than mice immunized with either single modality alone. DNA-primed/adenovirus-boosted mice also had significantly higher antibody and toxin-neutralizing titers than mice immunized with Anthrax Vaccine Adsorbed. High levels of antigen-specific interferon-gamma-secreting cells were present in vaccinated mice indicating that a cell-mediated immune response had also been stimulated. Both DNA-primed/adenovirus-boosted and adenovirus-primed/adenovirus-boosted mice were fully protected from Sterne strain spore challenge. We also show that a single injection with an adenovirus vector-expressing domain four of PA can provide partial protection from spore challenge 2 weeks after immunization and full protection 3 weeks after immunization. These results demonstrate that adenovirus-based prime-boost vaccination can provide rapid protection from anthrax and that this approach may be an effective strategy for immunizing against bacterial as well as viral pathogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17164792     DOI: 10.1038/sj.mt.6300034

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  18 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

3.  Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.

Authors:  Kristin H Clement; Thomas L Rudge; Heather J Mayfield; Lena A Carlton; Arelis Hester; Nancy A Niemuth; Carol L Sabourin; April M Brys; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

Review 4.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

5.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

6.  Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis.

Authors:  Kevin L Schully; Sadhana Sharma; Kevin J Peine; John Pesce; Margret A Elberson; Mariko E Fonseca; Angela M Prouty; Matthew G Bell; Hassan Borteh; Matthew Gallovic; Eric M Bachelder; Andrea Keane-Myers; Kristy M Ainslie
Journal:  Pharm Res       Date:  2013-01-25       Impact factor: 4.200

7.  An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.

Authors:  Jianfeng Zhang; Edward Jex; Tsungwei Feng; Gloria S Sivko; Leslie W Baillie; Stanley Goldman; Kent R Van Kampen; De-chu C Tang
Journal:  Clin Vaccine Immunol       Date:  2012-10-24

8.  Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.

Authors:  Hong-Duck Kim; Jing-Ji Jin; J Adam Maxwell; Ken-ichiro Fukuchi
Journal:  Immunol Lett       Date:  2007-07-23       Impact factor: 3.685

9.  Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

Authors:  Neetu Singh; Aseem Pandey; Lakshmi Jayashankar; Suresh K Mittal
Journal:  Mol Ther       Date:  2008-02-26       Impact factor: 11.454

10.  Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.

Authors:  Shipo Wu; Zhe Zhang; Rui Yu; Jun Zhang; Ying Liu; Xiaohong Song; Shaoqiong Yi; Ju Liu; Jianqin Chen; Ying Yin; Junjie Xu; Lihua Hou; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2013-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.